Pipeline
INDICATION
PRE-CLINICAL
CLINICAL
Diabetic Foot Ulcers (DFU) hOMSC200
POC
Safety
Phase I/IIa
Phase II
Phase III
*
Q1 2026
Mutiple System Atrophy (MSA) hOMSC300
**
Q4 2026
Peripheral Nerve Repair
CNS (Parkinson, Alzheimer)
Non-healing skeletal defects
Autoimmune, Psoriasis
*Preliminary Clinical Results: Indicate that hOMSC200 is safe. Preliminary efficacy results indicate significant superiority for the hOMSC200 compared to placebo. Clinical trial nr: NCT06003530.
**Study Ongoing: Positive safety results, trends in efficacy. Clinical trial nr: NCT05698017
Current Applications
Diabetic Wound Healing
• hOMSC200 for Diabetic Foot Ulcers.
• Diabetic Foot Ulcer (DFU) – Successful completion of Phase I/IIa clinical trial Q1/25.
Central & Autonomic Nervous System
• hOMSC300 for Multiple System Atrophy patients.
• Multiple System Atrophy (MSA) – Phase I Clinical Studies in progress.
Patent Protected IP
Cytora is the only company that holds an exclusive license for the production & commercialization of hOMSC.
4 Patent families
7 Granted patents
9 Patent applications
hOMSC themselves, their production and their use for any purpose are protected by granted patents
(US, Europe, China, India).
